Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

In other recent news, Sangamo Therapeutics has entered into a significant licensing agreement with Eli Lilly, granting Lilly exclusive rights to use Sangamo’s STAC-BBB capsid technology.

STAC-BBB shows widespread neuronal transduction across all cortical regions, according to Sangamo. Sangamo Therapeutics was hit hard by the loss of Pfizer as a partner at the end of last year, but ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

April 03, 2025--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM Sangamo (SGMO) delivered earnings and ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used to | ...

This is a daily list of top performers for high school softball in the Springfield area for May 5-10, including Gillespie's ...

Lily Woodworth, Buffalo Tri-City ... the top of the ninth inning and the Cardinals outdueled the Trojans in the Sangamo Conference. Shimkus finished 2-for-4 with five RBIs.

In other recent news, Sangamo Therapeutics has entered into a significant licensing agreement with Eli Lilly, granting Lilly exclusive rights to use Sangamo’s STAC-BBB capsid technology. This deal ...

Sangamo Therapeutics SGMO announced that its ... Novo Nordisk rose the most (0.2%), while Lilly declined the most (2.2%). In the past six months too, while AbbVie rose the most (9.7%), Novo ...